Skip to content

A study on first-line therapy for Helicobacter pylori infection in patients with penicillin allergy using a bismuth-containing quadruple therapy with rabeprazole, cefuroxime, and doxycycline

A study on first-line therapy for Helicobacter pylori infection in patients with penicillin allergy using a bismuth-containing quadruple therapy with rabeprazole, cefuroxime, and doxycycline

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076151
Enrollment
Unknown
Registered
2023-09-26
Start date
2023-09-30
Completion date
Unknown
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

experimental group:Bismuth-Containing Quadruple Therapy

Sponsors

The First Affiliated Hospital, Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Participants aged 18–65 years; 2. No history of of receiving H. pylori eradication therapy; 3. Confirmed H. pylori infection by at least one of the following tests: urea breath test, histology exam and positive bacterial culture.4.History of penicillin allergy or positive penicillin allergy test.

Exclusion criteria

Exclusion criteria: 1. Used antibiotics,bismuth,or acid inhibitor use, including H2 receptor antagonist, PPI or P-CAB within four weeks before inclusion; 2. Current pregnancy or breastfeeding; 3. Allergy to any of the study drugs; 4. History of gastrectomy; 5. Gastric malignancy; 6. Gastroduodenal ulcer with recent hemorrhage or signs of hemorrhage within 4 weeks; 7. Preexisting serious diseases or clinical conditions that might interfere with the evaluation of study treatment; 8. Hepatic or renal dysfunction; 9. Patients with prolonged QT interval, a history of ventricular arrhythmia, or hypokalemia; 10. Administration of astemizole, cisapride, pimozide, terfenadine, ergotamine/Dihydroergotamine, oral midazolam, colchicine, ticagrelor/ranolazine, statins, azanavir, or lipivirin during the trial.

Design outcomes

Primary

MeasureTime frame
Eradication rates of Helicobacter pylori;

Secondary

MeasureTime frame
adverse events;compliance;

Countries

China

Contacts

Public ContactYan Zhang

The First Affiliated Hospital, Ningbo University

nblc3344@163.com+86 137 3580 5711

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026